

# David Chatenet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5874796/publications.pdf>

Version: 2024-02-01

72  
papers

1,738  
citations

257450

24  
h-index

302126

39  
g-index

75  
all docs

75  
docs citations

75  
times ranked

1561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. <i>Peptides</i> , 2004, 25, 1819-1830.	2.4	95
2	Urotensin II, from fish to human. <i>Annals of the New York Academy of Sciences</i> , 2010, 1200, 53-66.	3.8	90
3	International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II-Related Peptide, and Their Receptor: From Structure to Function. <i>Pharmacological Reviews</i> , 2015, 67, 214-258.	16.0	82
4	Structure-Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 77-88.	5.2	76
5	Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord. <i>Journal of Neurochemistry</i> , 2006, 99, 616-627.	3.9	69
6	Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat. <i>Journal of Comparative Neurology</i> , 2007, 503, 573-591.	1.6	65
7	Localization of the urotensin II receptor in the rat central nervous system. <i>Journal of Comparative Neurology</i> , 2006, 495, 21-36.	1.6	60
8	Structure-activity relationships of urotensin II and URP. <i>Peptides</i> , 2008, 29, 658-673.	2.4	56
9	Biochemical and functional characterization of high-affinity urotensin-II receptors in rat cortical astrocytes. <i>Journal of Neurochemistry</i> , 2006, 99, 582-595.	3.9	50
10	The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. <i>Biochemical Journal</i> , 2010, 428, 113-124.	3.7	50
11	Behavioral effects of urotensin-II centrally administered in mice. <i>Psychopharmacology</i> , 2005, 183, 103-117.	3.1	47
12	Regulation of cardiac nitric oxide signaling by nuclear $\beta^2$ -adrenergic and endothelin receptors. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 62, 58-68.	1.9	45
13	Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. <i>European Journal of Endocrinology</i> , 2004, 151, 803-809.	3.7	44
14	Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model. <i>Neuropharmacology</i> , 2016, 108, 440-450.	4.1	44
15	Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca <sup>2+</sup> in adult cardiac myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 62, 189-202.	1.9	43
16	Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	43
17	Targeting the PAC1 Receptor for Neurological and Metabolic Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1399-1417.	2.1	43
18	Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. <i>Journal of Neurochemistry</i> , 2004, 91, 110-118.	3.9	40

#	ARTICLE	IF	CITATIONS
19	Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. <i>Journal of Neurochemistry</i> , 2008, 107, 361-374.	3.9	40
20	Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. <i>Biochemical Pharmacology</i> , 2011, 81, 552-561.	4.4	40
21	Discovery of new antagonists aimed at discriminating U <sub>1</sub> and U <sub>2</sub> -mediated biological activities: insight into U <sub>1</sub> and U <sub>2</sub> receptor activation. <i>British Journal of Pharmacology</i> , 2013, 168, 807-821.	5.4	31
22	Structure-Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7234-7238.	6.4	30
23	Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 940-949.	4.1	29
24	Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP. <i>FEBS Letters</i> , 2014, 588, 4590-4596.	2.8	27
25	Urotensin II <sup>(4-11)</sup> Azasulfuryl Peptides: Synthesis and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4740-4752.	6.4	27
26	<i>De Novo</i> Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolidiazepin-2-one <sup>13</sup> C-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction <i>in Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4624-4637.	6.4	26
27	Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. <i>Biochemical Pharmacology</i> , 2012, 83, 608-615.	4.4	25
28	Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity. <i>PLoS ONE</i> , 2017, 12, e0173783.	2.5	23
29	Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 688-695.	3.8	22
30	Cardiotoxin $\kappa$ : An Unexpectedly Potent Insulinotropic Agent. <i>ChemBioChem</i> , 2012, 13, 1805-1812.	2.6	21
31	Update on the urotensinerpic system: new trends in receptor localization, activation, and drug design. <i>Frontiers in Endocrinology</i> , 2013, 3, 174.	3.5	21
32	Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. <i>Oncotarget</i> , 2015, 6, 40970-40980.	1.8	21
33	Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide. <i>Journal of Controlled Release</i> , 2012, 163, 256-265.	9.9	20
34	Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9838-9859.	6.4	18
35	Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1455-1467.	6.4	18
36	Photoreleasable ligands to study intracrine angiotensin II signalling. <i>Journal of Physiology</i> , 2015, 593, 521-539.	2.9	16

#	ARTICLE	IF	CITATIONS
37	Development and Pharmacological Characterization of Conformationally Constrained Urotensin II-Related Peptide Agonists. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9612-9622.	6.4	15
38	Caged ligands to study the role of intracellular GPCRs. <i>Methods</i> , 2016, 92, 72-77.	3.8	15
39	Presence of urotensin-II receptors at the cell nucleus: Specific tissue distribution and hypoxia-induced modulation. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 639-647.	2.8	13
40	Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8707-8716.	6.4	12
41	Catabolism of the octadecaneuropeptide ODN by prolyl endopeptidase: Identification of an unusual cleavage site. <i>Peptides</i> , 2006, 27, 1561-1569.	2.4	11
42	Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats. <i>Experimental Neurology</i> , 2008, 210, 577-584.	4.1	11
43	Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. <i>EJNMMI Research</i> , 2011, 1, 21.	2.5	11
44	Design of a Truncated Cardiotoxin-I Analogue with Potent Insulinotropic Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2623-2633.	6.4	11
45	Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3412-3416.	2.2	11
46	New insights about the peculiar role of the 28-38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection. <i>Biochemical Pharmacology</i> , 2018, 154, 193-202.	4.4	10
47	Towards Targeting the Urotensinergic System: Overview and Challenges. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 725-734.	8.7	10
48	Synthesis of P-chiral enephosphonic acid derivatives. <i>Journal of Organometallic Chemistry</i> , 2002, 662, 83-97.	1.8	9
49	Insight into the role of urotensin II-related peptide tyrosine residue in UT activation. <i>Biochemical Pharmacology</i> , 2017, 144, 100-107.	4.4	9
50	[Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes. <i>Peptides</i> , 2008, 29, 813-819.	2.4	8
51	Effect of GABAA receptor activation on UT-coupled signaling pathways in rat cortical astrocytes. <i>Peptides</i> , 2008, 29, 727-734.	2.4	8
52	Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging. <i>European Journal of Pharmacology</i> , 2009, 617, 118-123.	3.5	8
53	Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in a structure-activity relationship study of a class B GPCR ligand. <i>European Journal of Medicinal Chemistry</i> , 2015, 104, 106-114.	5.5	7
54	Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide. <i>PLoS ONE</i> , 2018, 13, e0207366.	2.5	7

#	ARTICLE	IF	CITATIONS
55	Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 129398.	2.4	7
56	Spt5 Phosphorylation and the Rtf1 Plus3 Domain Promote Rtf1 Function through Distinct Mechanisms. <i>Molecular and Cellular Biology</i> , 2020, 40, .	2.3	7
57	New directions for urotensin II receptor ligands. <i>Peptide Science</i> , 2019, 111, e24056.	1.8	6
58	Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine. <i>Nuclear Medicine and Biology</i> , 2011, 38, 867-874.	0.6	5
59	The amidated PACAP1â€“23 fragment is a potent reduced-size neuroprotective agent. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 129410.	2.4	5
60	Perturbing dimer interactions and allosteric communication modulates the immunosuppressive activity of human galectin-7. <i>Journal of Biological Chemistry</i> , 2021, 297, 101308.	3.4	5
61	Binding of a Soluble <i>meso</i>-Tetraarylporphyrin to Human Galectin-7 Induces Oligomerization and Modulates Its Pro-Apoptotic Activity. <i>Biochemistry</i> , 2020, 59, 4591-4600.	2.5	4
62	Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands. <i>Journal of Biological Chemistry</i> , 2021, 297, 101057.	3.4	4
63	Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1717-1722.	2.8	3
64	A New Approach to Inhibit Prototypic Galectins. <i>Trends in Glycoscience and Glycotechnology</i> , 2018, 30, SE155-SE165.	0.1	2
65	PACAP-Derived Carriers: Mechanisms and Applications. <i>Current Topics in Neurotoxicity</i> , 2016, , 133-148.	0.4	2
66	Exploring the use of intracellular and extracellular allosteric modulators to understand GPCR signaling. , 2022, , 135-160.		2
67	Understanding GPCR signaling in the brain- the path to CNS drug discovery. <i>Current Opinion in Pharmacology</i> , 2017, 32, v-vii.	3.5	1
68	The Pharmacophoric Determinants of PACAP. <i>Current Topics in Neurotoxicity</i> , 2016, , 111-132.	0.4	1
69	Design and Application of Light-Activated Probes for Cellular Signaling. <i>Methods in Molecular Biology</i> , 2015, 1234, 17-30.	0.9	1
70	PACAP. , 2013, , 1038-1043.		0
71	Synthesis of N-Methyl and Azasulfuryl Urotensin-II(4-11) Derivatives. , 2015, , .		0
72	Design of peptidic inhibitors targeting the dimerization interface of galectins. <i>Acta Crystallographica Section A: Foundations and Advances</i> , 2017, 73, C99-C99.	0.1	0